TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Dexmedetomidine & EC50 of Propofol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-II patients who were 20-65 years old and scheduled for general anaesthesia for urologic surgery~Exclusion Criteria:~* Patients with an allergy to alpha-2 adrenergic agonists or propofol~* Patients who anticipated difficult airway (cervical spinal disease, Mallampati score of III or IV, a mouth opening of \<2.5 cm, and/or body mass index of \>30 kg m-2), unstable teeth~* Patients with bradycardia of \<50 beats/min, heart block greater than first degree, severe cardiorespiratory dysfunction~* Patients with symptoms of upper respiratory infection

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group D : Dexmedetomidine + propofol group (Type: EXPERIMENTAL): In Group D, DEX (1 µg kg-1) was intravenously loaded for 10 min before induction of anaesthesia.
- Group C : Saline + propofol group (Type: PLACEBO_COMPARATOR): In Group C, 0.9% of normal saline (1 µg kg-1) was loaded 10 min before induction of anaeshtesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and/or non-pregnant, non-lactating or postmenopausal females, between 18 and 55 years of age with a body mass index ≥ 19 and ≤ 30 kg/m2.~2. All subjects biologically capable of having children must agree and commit to the use acceptable method(s) of birth control.~Exclusion Criteria:~1. ECG abnormalities or lab values greater than 2 times the upper limit of normal.~2. Positive test results for human immunodeficiency virus (HIV), hepatitis B (HBsAg), or hepatitis C (IgG).~3. Positive urine test results for drugs of abuse or history of drug/alcohol abuse.~4. Use of marijuana, illicit drugs or nicotine-containing products.~5. Donated or had significant loss of whole blood.~6. Taken any prescription or nonprescription drugs, vitamins, minerals, or dietary/herbal supplements.~7. History of abdominal and/or pelvic surgery, cholecystectomy, gastric bypass or gastric band surgery, or cardiothoracic surgery.~8. History of anxiety, tension, agitation, psychiatric disorders, psychosis, or depression requiring hospitalization, psychotherapy, and/or medication.~9. History of acute or chronic gastrointestinal disease or any condition that may interfere with the absorption, distribution, metabolism or excretion of the study treatment.~10. History of seizures or diagnosis of epilepsy or other seizure disorder.~11. History or laboratory evidence of bleeding or clotting disorder or condition.~12. History or laboratory evidence of malignancy, stroke, diabetes, cardiac, renal, liver, and chronic pulmonary disease.~13. Have or have a history of hay fever or seasonal allergies requiring over-the-counter or prescription medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- COV155 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent obtained before any trial-related activities. (Trial activities are any procedure that would not have been performed during normal management of the subject).~* Nonsmoker~* Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant~* Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant~* If female and of childbearing potential and subjects agrees to employ adequate birth control measures (e. g. oral contraceptives, barrier method)~* Negative urine pregnancy test~Exclusion Criteria:~* Known or suspected allergy to trial product or related products~* Pregnancy or Lactation~* Treatment with an investigational drug within three weeks prior to this trial~* Participation in an LPS trial within the last 6 weeks~* Smoking~* History of relevant cardiac arrhythmia~* Preexisting open or closed angle glaucoma~* History of Osteoporosis, Cushing´s syndrome, gastro-duodenal ulcera, cardiovascular disease, vasculitis, diabetes mellitus, hypertension, brain tumor or history of neurosurgery~* Systemic tuberculosis~* Hemorrhagic diathesis~* Relevant liver or kidney dysfunction~* Regular use of medication or abuse of alcohol unless considered clinically relevant~* Use of any medication within one week prior to the first trial day~* Symptoms of a clinically relevant illness in the 3 weeks before the first trial day~* Excessive sporting activities~* Rosacea~* Subjects on Monoamine oxidase inhibitors (should be stopped for at least two to three weeks before dihydrocodeine treatment is initiate)~* Known acute or active hepatic disease within the past 3 months~* A platelet count \< 100,000 x 106/L, prothrombin time \> 1.5, liver enzymes\> 3 times the upper normal limit~* Having received a vaccination up to 8 weeks before the trial

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): None
- Sterile isotonic saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 45 years~* Established diagnosis of SCD-SS or SCD-SB0-thal~* At medical baseline, with no evidence of worsening of disease over the last 3 months~* Available and agree to return for follow-up visits for the full duration of the study~* Able to cooperate with study procedures~* Documented and observed written informed consent~Exclusion Criteria:~* Vaso-occlusive crisis~* Recent major surgery, hospitalization, infection, significant bleeding, cerebrovascular accident or seizure, or transfusion~* Currently receiving, or has received within the previous 4 weeks, any other investigational agent~* Pregnant or lactating female; or female of childbearing age unable or unwilling to comply with birth control or abstinence during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- GMI-1070 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Community-dwelling patients ≥ 18 years of age with incurable,histologically diagnosed cancer.~* Involuntary loss of body weight of ≥ 5 % within the past 6 months~Exclusion Criteria:~* Presently hospitalized or in a nursing care facility.~* Inability to increase food intake from secondary causes.~* Liver disease~* If female-pregnant, breast-feeding or of childbearing potential.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RC-1291 HCl (Type: ACTIVE_COMPARATOR): 50 mg
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Lipophilic Versus Hydrophilic Statins on Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* older than 18 years (of both sexes)~* diagnosed with stable chronic heart failure NYHA class II-III~* ejection fraction \< 40 % as assessed by 2D echocardiography~* who have been optimized on Guideline Directed treatment for heart failure for at least a month prior to enrolling.~Exclusion Criteria:~* Known hypersensitivity to statin~* Treatment with statins during the past month prior to study.~* Serum creatinine \> 3 mg/dl~* Significant liver disease: liver enzymes 2.5 folds the upper normal limit~* Malignancy~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lipophilic statin (Type: ACTIVE_COMPARATOR): Atorvastatin 40 mg administered daily in addition to guideline directed therapy for heart failure.
- Hydrophilic statin (Type: ACTIVE_COMPARATOR): Rosuvastatin 20 mg administered daily in addition to guideline directed therapy for heart failure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for surgery with anticipated need for postoperative analgesia~Exclusion Criteria:~1. Patients with inadequate IV access~2. Patients \<18 years of age~3. History or allergy or hypersensitivity to any component of intravenous ibuprofen, aspirin (or aspirin related products) or non-steroidal anti-inflammatory drug (NSAIDs)~4. Active hemorrhage or clinically significant bleeding~5. Pregnant or nursing~6. Patients in the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery~7. Inability to understand the requirements of the study, be willing to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board \[IRB\]), and agree to abide by the study restrictions~8. Refusal to provide written authorization for use and disclosure of protected health information

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous ibuprofen (Type: EXPERIMENTAL): Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of rheumatoid arthritis, Crohn's disease or psoriasis who have made a decision with their physician to commence treatment with adalimumab in accordance with routine medical practice and with the approved adalimumab New Zealand Datasheet.~* Patients who have been evaluated for tuberculosis risk factors/exposure for active/latent tuberculosis infection (per local requirements and according to the approved adalimumab New Zealand Datasheet).~* Adult subjects, 18-75 years old, who have voluntarily signed and dated an informed consent form prior to any study-specific procedures.~Exclusion Criteria:~* Previous treatment with adalimumab.~* Previous treatment with any biologic.~* Severe infection including sepsis, active tuberculosis or opportunistic infection.~* Moderate to severe heart failure (New York Heart Association Class II/III).~* Concurrent administration with anakinra.~* Hypersensitivity to adalimumab or its excipients.~* Any condition that in the opinion of the investigator would compromise the subject's well-being or ability to perform the study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Crohn's Disease (Type: None): Participants with Crohn's disease. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
- Rheumatoid Arthritis (Type: None): Participants with rheumatoid arthritis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
- Psoriasis (Type: None): Participants with psoriasis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid in Knee Joint Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients at the participating sites on the waiting list for a unilateral total knee joint replacement~Exclusion Criteria:~* Patients with a history or risk of thrombosis~* Active thromboembolic disease such as deep vein thrombosis, pulmonary embolism and cerebral thrombosis~* Subarachnoid haemorrhage~* Hypersensitivity to tranexamic acid or any of its ingredients.~* Refusal of blood products~* Colour blindness~* Complex hematologic disorders requiring manipulation~* Coagulopathy~* Pregnant and Lactating Women~* Anti-coagulant therapy pre-operatively within 5 days of surgery (warfarin, dabigatran, heparin)~* Severe renal failure (eGFR \<29)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Application of 20ml of normal saline (NaCl 0.9%) topically after implantation of prosthesis and left to sit for two minutes, excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
- Topical (Type: EXPERIMENTAL): Application of 1.5g in 20ml tranexamic acid topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
- Systemic (Type: EXPERIMENTAL): Application of 20ml of normal saline topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; Application of tranexamic acid intravenously (1.5g/15ml) at the same time prior to release of tourniquet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has idiopathic Parkinson's disease (early- or advanced-stage), as defined by the cardinal sign bradykinesia, plus the presence of at least one of the following: resting tremor, rigidity, or postural instability and is without any other known or suspected cause of Parkinsonism.~* Subject is scheduled for an operation requiring general anesthesia.~Exclusion Criteria:~* Subject has previously been treated with rotigotine.~* Subject has a history of significant skin hypersensitivity to adhesives or other transdermals or recent unresolved contact dermatitis or has a known allergy or hypersensitivity to rotigotine or to other components of the patch.~* Subject is scheduled for a surgical procedure (surgery per protocol(SPP)) that requires magnetic resonance imaging or cardioversion.~* Subject has a high probability to require extended postoperative ventilation (\> 24 hours).~* Subject has any medical condition that, in the opinion of the investigator, could jeopardize or compromise the subject's ability to participate in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Rotigotine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had stable moderate to severe plaque psoriasis for at least 6 months~* Subject has involved BSA ≥ 10% and PASI ≥ 10 at screening and at baseline.~* Subject is a candidate for systemic therapy or phototherapy in the opinion of the investigator~Exclusion Criteria:~* Subject has active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit.~* Subject has evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of etanercept and/orclobetasol propionate foam on psoriasis.~* Subject diagnosed with medication-induced or medication exacerbated psoriasis~* Subject has any active Common Toxicity Criteria (CTC) grade 2 or higher infection~* Subject has a significant concurrent medical condition or laboratory abnormalities as defined in the study protocol.~* Subject has used any of the following therapies within 14 days of the first dose: UVB therapy or topical psoriasis therapies other than Class I or II topical steroids.~* Subject has used any of the following therapies within 28 days of the first dose: Class I or II topical steriods, UVA therapy (with or without psoralen), or systemic psoriasis therapies~* Subject has used one or more biologic therapies (other than interleukin (IL)12/IL23 inhibitors) within 3 months of the first dose~* Subject has used an IL-12/IL-23 inhibitor within 6 months of the first dose of etanercept~* Subject has ever used efalizumab (Raptiva®).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- etanercept and clobetasol (Type: EXPERIMENTAL): Etanercept 50 mg twice weekly x 12 weeks + clobetasol propionate foam (weeks 11 and 12) then Etanercept 50 mg once weekly x 12 weeks + clobetasol propionate foam (weeks 23 and 24)
- etanercept (Type: EXPERIMENTAL): Etanercept 50 mg twice weekly x 12 weeks then Etanercept 50 mg once weekly x 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Type 2 Diabetes Mellitus (T2DM) diagnosed ≤ 24 months ago~* glycosylated hemoglobin (HbA1c) ≥6.5% and ≤7.5% at Visit 1~* Treatment-naïve.~* Body mass index (BMI) ≥22 and ≤40 kg/m2 at Visit 1~Key Exclusion Criteria:~* Pregnant or nursing (lactating) women~* Fasting plasma glucose (FPG) ≥ 270 mg/dL (≥ 15.0 mmol/L)~* Previous or current participation in any vildagliptin clinical study.~* History of hypersensitivity to dipeptidyl peptidase-4 (DPP-4) inhibitors.~* Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.~* Donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Vilda 50mg bid + metformin (Type: ACTIVE_COMPARATOR): Metformin + vildagliptin
- Placebo + metformin (Type: EXPERIMENTAL): Metformin + Placebo of vildagliptin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete